The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksShire Share News (SHP)

  • There is currently no data for SHP

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

WINNERS & LOSERS SUMMARY: Shire Rises As US FDA Approves Takhzyro Drug

Fri, 24th Aug 2018 10:39

LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Friday.----------FTSE 100 - WINNERS----------Shire, up 2.6%. The Irish pharmaceutical company said the US Food & Drug Administration has approved its Takhzyro drug to treat a rare genetic disease. The disease, hereditary angioedema, causes attacks of swelling in different parts of the body and can be life-threatening. Approval from the FDA follows a phase III study of 125 patients in which Takhzyro reduced monthly attacks by, on average, 87% in patients when compared with a placebo. Antofagasta, up 2.0%. RBC Capital upgraded the Chilean copper miner to Outperform from Sector Perform. ----------FTSE 100 - LOSERS----------Berkeley Group, down 2.3%, Barratt Developments, down 1.9%, Persimmon, down 1.7%, Taylor Wimpey, down 1.2%. The housebuilders were lower amid a decline in UK mortgage approvals in July. The number of mortgages approved in July fell to 39,584 from 40,330 in June. Economists had forecast approvals to rise to 40,650, data from UK Finance showed. "Housebuilders have taken a knock as a double whammy of lower new approved mortgages and a five-month low in mortgage lending weighed on the sector," IG Group analyst Chris Beauchamp said. Midcap peers McCarthy & Stone, Bovis Homes and Bellway were down 2.1%, 1.4% and 1.2%, respectively. ----------FTSE 250 - WINNERS----------Ted Baker, up 2.0%. Peel Hunt raised the high street fashion retailer to Add from Hold. ----------OTHER MAIN MARKET AND AIM - WINNERS----------Henry Boot, up 4.5%. The construction company said interim profit and revenue both rose in an "impressive" first half performance. For the six months to June, Henry Boot's pretax profit was up 16% to GBP26.2 million, while revenue rose slightly to GBP196.2 million from GBP195.4 million a year prior. Its net asset value per share increased by 18% to 217 pence. Henry Boot is paying an interim dividend to shareholders of 3.20p, from 2.80p a year prior. The company said it has seen "consistent" levels of demand across all of its businesses in the first half of 2018, particularly in housing development land. ----------OTHER MAIN MARKET AND AIM - LOSERS----------Bahamas Petroleum, down 63%. The oil and gas explorer said its exclusivity agreement with a major international oil company will terminate at the end of the month. The unnamed international company has notified Bahamas that it will not be extending the agreement, which has been in place since the start of May, past next Friday and will cease exclusivity payments. Bahamas said it has recommenced broader asset-based discussions with third parties. These will continue alongside the ongoing non asset-based discussions which surround the funding of its first exploration well.----------
More News
6 Sep 2019 07:54

UPDATE 1-Sumitomo Dainippon Pharma investing $3 bln in Swiss Roivant in overseas push

* Dainippon to buy 10% stake in Roivant and interests in 5 units * Schizophrenia treatment Latuda to lose US exclusivity in 2023 * Japan pharma firms grapple with declining Dainippon

Read more
14 Aug 2019 06:45

UPDATE 1-Germany's Stada 'very selective' on acquisitions - CEO Goldschmidt

FRANKFURT, Aug 14 (Reuters) - German generic drugmaker Stada will be careful about buying businesses and companies outright, and for now will focus mainly on striking production and development we

Read more
17 Jul 2019 17:55

Takeda kicks off sale of Western European drugs - sources

By Arno Schuetze and Pamela Barbaglia FRANKFURT/LONDON, July 17 (Reuters) - Japan's Takeda Pharmaceutical Co has reached out to prospective bidders for a portfolio of drugs for sale in

Read more
16 May 2019 18:35

Japan's Takeda expects binding offers for Latam business by end of May -sources

By Tatiana Bautzer SAO PAULO, May 16 (Reuters) - Japan's Takeda Pharmaceutical Co expects to receive binding offers for its Latin American business by the end of May, three sources of a

Read more
15 May 2019 08:05

Nikkei snaps 7-day losing streak helped by China's stimulus hopes

* Gains may be short-lived - analyst * Takeda Pharma, Nissan sink after earnings shock * Mitsubishi Estate jumps on share buyback, governance reform By Hideyuki Sano and Ayai

Read more
15 May 2019 04:04

Nikkei hobbled by trade worries, disappointing earnings

* Nikkei down slightly after 7 losing sessions * Uncertainties over U.S.-China standoff keep investors on edge * Takeda Pharma, Nissan sink after earnings shock * Mitsubishi -

Read more
14 May 2019 07:56

UPDATE 1-Japan's Takeda forecasts 193 bln yen annual operating loss on Shire deal

* 193 bln Y op loss forecast this yr vs 227.5 bln profit view of analysts * Shire acquisition made Takeda one of the world's most indebted drugmakers (Adds details of results, May 14 -

Read more
14 May 2019 07:39

Japan's Takeda expects annual loss on Shire deal

TOKYO, May 14 (Reuters) - Takeda Pharmaceutical Co forecast on Tuesday it would have an operating loss in the current financial year, as it books costs associated with the multibillion-dollar an a

Read more
9 May 2019 00:38

UPDATE 1-Novartis buys Takeda's dry eye drug for $3.4 bln

May 8 (Reuters) - Swiss drugmaker Novartis AG said on Wednesday it agreed to acquire Takeda Pharmaceutical Company Ltd's dry eye drug Xiidra for $3.4 billion, as well as potential milestone of

Read more
1 Feb 2019 06:07

Japan's Takeda posts 28 pct rise in Q3 operating profit

TOKYO, Feb 1 (Reuters) - Takeda Pharmaceutical Co Ltd on Friday posted a 27.9 percent rise in third-quarter operating profit, supported by strong sales of its drugs for bowel disease and multiple

Read more
22 Jan 2019 02:46

Nikkei dips as global growth concerns sap risk appetite

* IMF cuts global growth forecasts * Companies with big China exposure fall * Totech soars after raising earnings forecast By Ayai Tomisawa TOKYO, Jan 22 (Reuters) - in

Read more
8 Jan 2019 13:54

MARKET ANALYSIS: Optimism About Trade Talks May Generate Continued Buying Interest

WASHINGTON (Alliance News) - The major US index futures are pointing to a higher opening on Tuesday, with stocks likely to extend the strong upward move seen over the two previous about trade the

Read more
8 Jan 2019 08:58

Asian Shares Mixed Despite US-China Trade Deal Optimism

CANBERA (Alliance News) - Asian stocks ended mixed on Tuesday despite optimism over US-China trade talks as US officials held a second day of trade talks with Chinese counterparts in second day of

Read more
8 Jan 2019 07:39

Takeda takes control of Shire

(Sharecast News) - Takeda Pharmaceutical has taken full control of Shire after the legal particulars of its cash and share offer were completed.

Read more
7 Jan 2019 04:29

Takeda unlikely to sell OTC drug business -CEO

(Adds quote, other details) TOKYO, Jan 7 (Reuters) - Takeda Pharmaceutical is unlikely to sell its over-the-counter (OTC) drug business even amid pressure to improve its finances as it a a

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.